Novelstem Q2 net loss narrows to $85,795 from year-ago profit

• Novelstem posted a net loss of $140,816 for the six months ended June 30, 2026, swinging from net income of $2.55 million.
• Net loss was $85,795 for the three months ended June 30, 2026, turning from net income of $2.75 million.
• G&A expense fell 74.83% to $39,888 for the six-month period, driven by lower professional fees and discounted settlement of prior legal fees.
• Interest expense declined 38.44% to $100,928 for the six months, following the May 9, 2025 settlement of the litigation funding agreement.
• Current assets rose to about $65,000 at June 30, 2026, reflecting equity sales; current liabilities eased to $2.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novelstem International Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038089), on August 14, 2026, and is solely responsible for the information contained therein.